Pembrolizumab plus axitinib combination declined for first-line treatment of advanced kidney cancer

The National Institute for Health and Care Excellence (NICE) have issued a final decision not to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Final Appraisal Document (FAD) released today, NICE stated that there was uncertainty about the long-term benefits of the pembrolizumab plus axitinib […]

read more

Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer

KCSN are formal consultants to NICE and part of the process that appraises all new kidney cancer drugs. We are delighted to tell you that, as from today, kidney cancer patients can get NHS funding via the Cancer Drugs Fund for avelumab in combination with axitinib as a first-line treatment for patients with untreated advanced […]

read more

COVID-19: Doctors given new guidelines for treating patients in critical care

Amid concerns that the NHS will be overwhelmed by the demand for intensive care beds and ventilators during the coronavirus outbreak, the National Institute for Health and Care Excellence (NICE) have published guidelines to help doctors and nurses prioritise patients during the pandemic. The three new NICE guidelines cover patients needing critical care, kidney dialysis […]

read more

NICE draft guidance refuses pembrolizumab plus axitinib combination

The National Institute for Health and Care Excellence (NICE) have issued an interim decision not to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Appraisal Consultation Document (ACD) released this week, NICE stated that there was uncertainty about the long-term […]

read more

Research supports better integration of patient voice in health technology assessments

A report from Myeloma UK and the National Institute for Health and Care Excellence (NICE) outlines the findings from a study looking at how patient preferences could be more formally incorporated in health technology assessments (HTA). Feedback from a patient and family workshop demonstrated how myeloma impacts the lives of patients in different ways and […]

read more

NICE exploring ways to use real world data

The National Institute of Health and Care Excellence (NICE) is planning to extend its use of real world data to help inform its independent committees who produce its guidance. NICE already makes use of a wide range of published scientific evidence for its guidance for the NHS on health technologies for a range of medical […]

read more

First immunotherapy combination of ipilimumab plus nivolumab available to patients in England

We are very pleased to learn that the ipilimumab plus nivolumab combination has been endorsed for use by the National Institute for Health and Care Excellence (NICE) for poor- and intermediate-risk advanced renal cell carcinoma (RCC). The treatment will be made immediately available to patients in England via the Cancer Drugs Fund. The availability of […]

read more

New cancer drug payment system could speed up access to treatments

Cancer Research UK and the Greater Manchester Health and Social Care Partnership has produced a report suggesting a new system for reimbursement of cancer drugs by the NHS. The report suggests that paying for cancer drugs based on how well they work in practice could help patients get new treatments faster. This new flexible system, […]

read more

Cancer drugs taking longer to reach NHS patients

A new report by the Institute of Cancer Research (ICR) has found that patients are waiting longer for new cancer drugs to be approved for use with the NHS because of delays in clinical trials and regulatory approval for use. The report found that the average time taken from the start of phase I clinical […]

read more

NICE publishes final guidance for cabozantinib for untreated advanced renal cell carcinoma

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending use of cabozantinib (Cabometyx) as a treatment option for people with untreated advanced renal cell carcinoma (RCC). Clinical trials have shown that patients treated with cabozantinib in the first-line had a reduced risk of disease progression or death by 52% compared to patients treated with first-line […]

read more
Showing 1 to 10 of 34 results
  TOP